TY - JOUR
T1 - Diagnosis of Constitutional Mismatch Repair-Deficiency Syndrome Based on Microsatellite Instability and Lymphocyte Tolerance to Methylating Agents
AU - European Consortium #x22;Care for CMMRD#x22;
AU - Bodo, Sahra
AU - Colas, Chrystelle
AU - Buhard, Olivier
AU - Collura, Ada
AU - Tinat, Julie
AU - Lavoine, Noémie
AU - Guilloux, Agathe
AU - Chalastanis, Alexandra
AU - Lafitte, Philippe
AU - Coulet, Florence
AU - Buisine, Marie Pierre
AU - Ilencikova, Denisa
AU - Ruiz-Ponte, Clara
AU - Kinzel, Miriam
AU - Grandjouan, Sophie
AU - Brems, Hilde
AU - Lejeune, Sophie
AU - Blanché, Hélène
AU - Wang, Qing
AU - Caron, Olivier
AU - Cabaret, Odile
AU - Svrcek, Magali
AU - Vidaud, Dominique
AU - Parfait, Béatrice
AU - Verloes, Alain
AU - Knappe, Ulrich J.
AU - Soubrier, Florent
AU - Mortemousque, Isabelle
AU - Leis, Alexander
AU - Auclair-Perrossier, Jessie
AU - Frébourg, Thierry
AU - Fléjou, Jean François
AU - Entz-Werle, Natacha
AU - Leclerc, Julie
AU - Malka, David
AU - Cohen-Haguenauer, Odile
AU - Goldberg, Yael
AU - Gerdes, Anne Marie
AU - Fedhila, Faten
AU - Mathieu-Dramard, Michèle
AU - Hamelin, Richard
AU - Wafaa, Badre
AU - Gauthier-Villars, Marion
AU - Bourdeaut, Franck
AU - Sheridan, Eamonn
AU - Vasen, Hans
AU - Brugières, Laurence
AU - Wimmer, Katharina
AU - Muleris, Martine
AU - Duval, Alex
N1 - Publisher Copyright:
© 2015 AGA Institute.
PY - 2015/10/1
Y1 - 2015/10/1
N2 - Background & Aims Patients with bi-allelic germline mutations in mismatch repair (MMR) genes (MLH1, MSH2, MSH6, or PMS2) develop a rare but severe variant of Lynch syndrome called constitutional MMR deficiency (CMMRD). This syndrome is characterized by early-onset colorectal cancers, lymphomas or leukemias, and brain tumors. There is no satisfactory method for diagnosis of CMMRD because screens for mutations in MMR genes are noninformative for 30% of patients. MMR-deficient cancer cells are resistant to genotoxic agents and have microsatellite instability (MSI), due to accumulation of errors in repetitive DNA sequences. We investigated whether these features could be used to identify patients with CMMRD. Methods We examined MSI by PCR analysis and tolerance to methylating or thiopurine agents (functional characteristics of MMR-deficient tumor cells) in lymphoblastoid cells (LCs) from 3 patients with CMMRD and 5 individuals with MMR-proficient LCs (controls). Using these assays, we defined experimental parameters that allowed discrimination of a series of 14 patients with CMMRD from 52 controls (training set). We then used the same parameters to assess 23 patients with clinical but not genetic features of CMMRD. Results In the training set, we identified parameters, based on MSI and LC tolerance to methylation, that detected patients with CMMRD vs controls with 100% sensitivity and 100% specificity. Among 23 patients suspected of having CMMRD, 6 had MSI and LC tolerance to methylation (CMMRD highly probable), 15 had neither MSI nor LC tolerance to methylation (unlikely to have CMMRD), and 2 were considered doubtful for CMMRD based on having only 1 of the 2 features. Conclusion The presence of MSI and tolerance to methylation in LCs identified patients with CMMRD with 100% sensitivity and specificity. These features could be used in diagnosis of patients.
AB - Background & Aims Patients with bi-allelic germline mutations in mismatch repair (MMR) genes (MLH1, MSH2, MSH6, or PMS2) develop a rare but severe variant of Lynch syndrome called constitutional MMR deficiency (CMMRD). This syndrome is characterized by early-onset colorectal cancers, lymphomas or leukemias, and brain tumors. There is no satisfactory method for diagnosis of CMMRD because screens for mutations in MMR genes are noninformative for 30% of patients. MMR-deficient cancer cells are resistant to genotoxic agents and have microsatellite instability (MSI), due to accumulation of errors in repetitive DNA sequences. We investigated whether these features could be used to identify patients with CMMRD. Methods We examined MSI by PCR analysis and tolerance to methylating or thiopurine agents (functional characteristics of MMR-deficient tumor cells) in lymphoblastoid cells (LCs) from 3 patients with CMMRD and 5 individuals with MMR-proficient LCs (controls). Using these assays, we defined experimental parameters that allowed discrimination of a series of 14 patients with CMMRD from 52 controls (training set). We then used the same parameters to assess 23 patients with clinical but not genetic features of CMMRD. Results In the training set, we identified parameters, based on MSI and LC tolerance to methylation, that detected patients with CMMRD vs controls with 100% sensitivity and 100% specificity. Among 23 patients suspected of having CMMRD, 6 had MSI and LC tolerance to methylation (CMMRD highly probable), 15 had neither MSI nor LC tolerance to methylation (unlikely to have CMMRD), and 2 were considered doubtful for CMMRD based on having only 1 of the 2 features. Conclusion The presence of MSI and tolerance to methylation in LCs identified patients with CMMRD with 100% sensitivity and specificity. These features could be used in diagnosis of patients.
KW - Colon Cancer
KW - Functional Tests
KW - Predisposition
KW - Tumor
UR - http://www.scopus.com/inward/record.url?scp=84942342366&partnerID=8YFLogxK
U2 - 10.1053/j.gastro.2015.06.013
DO - 10.1053/j.gastro.2015.06.013
M3 - Article
C2 - 26116798
AN - SCOPUS:84942342366
SN - 0016-5085
VL - 149
SP - 1017-1029.e3
JO - Gastroenterology
JF - Gastroenterology
IS - 4
M1 - 59847
ER -